



VISION ZERO CANCER

Financed by the Swedish
Innovation Agency

Agenda

Knowledge and experience exchange with Sweden: Early detection of lung cancer in never-smokers

Lung cancer accounts for one in five deaths worldwide. The past few years have seen considerable advances in treatment for lung cancer, yet the prognosis remains low. Lung cancer causes symptoms that come up late in the course of the disease and assessments are complicated. This means that half of the patients have a spread disease at diagnosis.

Early detection and prevention are the best strategies to improve the treatment outcome or eliminate the disease. People who smoke or have smoked have the greatest risk of lung cancer, though lung cancer also increasingly occur in people who have never smoked. Lung cancer in never-smokers is a global rising threat and there is growing pressure to understand how never-smokers' disease differs from that of smokers, and how to effectively prevent and diagnose early.

The purpose of this meeting is to share discoveries and experience on how to develop an effective preventive strategy.

Date: Tuesday 29 June 2021
Time: 14:00 - 16:00 CET (Sweden)
Place: <https://hhs-se.zoom.us/j/65628140682>

14:00 INTRODUCTORY REMARKS FROM SWEDEN

Working together across society in the mission of eliminating lung cancer as a cause of death

Hans Hägglund, MD, Professor, National Cancer Coordinator, Chairman of the Federation of Regional Cancer centres, Co-founder and Chairman of Vision Zero Cancer

Ebba Hallersjö Hult, Co-founder and Head of Vision Zero Cancer

How a lung cancer diagnosis became a driver for improving lungcancer care

Mia Rajalin, PhD., lic. psychologist, Director of Studies, Region Stockholm, Member of the Board, the Swedish Lung Cancer Association and Vision Zero Cancer

Early detection by symptoms as predictors of cancer in primary care

Eliya Abedi, MD, Specialist General Medicine, PhD student at Karolinska Institutet, research on early detection of cancer in primary care



VISION ZERO CANCER

Financed by the Swedish
Innovation Agency

14:20 KEYNOTE SPEECH: IMPLEMENTING LUNG CANCER SCREENING PROGRAM IN NEVER-SMOKERS IN EAST ASIA, FINDINGS FROM THE “TALENT” STUDY IN TAIWAN

A proteogenomics approach to identify the environmental carcinogen and endogenous genetic signatures as well as the pathogenic mechanisms of never smoker lung cancer in East Asia

Pan-Chyr Yang, MD, PhD, Chair Professor at the National Taiwan University Hospital and Academician of Academia Sinica, Taiwan

Dr. Yang is the former President of National Taiwan University and has been a professor in the department of internal medicine at the College of Medicine for 27 years. He has also served as the Director of the Advisory Office for the Ministry of Education for the Republic of China (Taiwan) and as Dean for the College of Medicine at National Taiwan University.

His current research focuses on lung cancer genomics, molecular mechanisms of cancer metastasis, and translational research related to precision therapy of lung cancer.

14:50 ROUNDTABLE DISCUSSION: HOW TO TRANSLATE CURRENT KNOWLEDGE INTO STRATEGIES TO REDUCE RISK AND IMPROVE SURVIVAL?

Participants:

Andrew Kaufman, MD, PhD, Associate Professor, thoracic surgeon at Mount Sinai Hospital in New York City, USA

Pan-Chyr Yang, MD, PhD, Chair Professor at the National Taiwan University Hospital and Academician of Academia Sinica, Taiwan

Kersti Oselin, MD, PhD, Medical Oncologist, North-Estonian Regional Hospital Cancer Center, Estonia

Marcela Ewing, MD, PhD, Specialist Oncology and General Medicine, Sahlgrenska Academy, Regional Lead Early Detection of Cancer, Confederation of Regional Cancer Centres, Sweden

Mattias Johansson, PhD, Scientist, Genetic Epidemiology Group, International Agency for Research on Cancer (IARC), World Health Organization

Mikael Johansson, MD, Associate Professor, Senior Consultant Oncology, Umeå University Hospital and Senior lecturer at Umeå University, Chair of the National Working Group for Lung Cancer Care, Sweden



VISION ZERO CANCER

Financed by the Swedish
Innovation Agency

Topics:

What can other countries learn from the new evidence of lung cancer risk provided in the TALENT study? Is it time to redefine screening eligibility?

Non-smoker susceptibility

Differences by sex in lung cancer incidence and mortality

How can we develop an effective preventive strategy to eliminate lung cancer as a cause of death?

How do we leverage the promise of precision cancer medicine for our lung cancer patients and societies?

Moderated by:

Suzanne Håkansson, Director Government Affairs AstraZeneca, Co-founder and Member of the Board of Vision Zero Cancer

Elin Fernholm Policy and Patient Affairs Manager, Oncology, AstraZeneca Sweden
Member of the Operations Team of Vision Zero Cancer

15:25

NEW TECHNOLOGIES FOR EARLY LUNG CANCER DETECTION

Using biomarkers to improve early detection for lung cancer

Mattias Johansson, PhD, Scientist, Genetic Epidemiology Group, International Agency for Research on Cancer (IARC), World Health Organization

AI for early detection and prognostic significance of genomic markers in lung cancer recurrence

Kersti Oselin, MD, PhD, Medical Oncologist, North-Estonian Regional Hospital Cancer Center

Lung cancer screening and innovation: The Integration and Analysis of Data using Artificial Intelligence to Improve Patient Outcomes with Thoracic Diseases (DART)

Amied Shadmaan, Director, AI & Clinical Collaborations, GE Healthcare

15:55

WAY FORWARD

16:00

END OF MEETING